Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma

Imre Rényi, Edit Bárdi, Erzsébet Udvardi, Gábor Kovács, Katalin Bartyik, Pál Kajtár, Péter Masát, Kálmán Nagy, Ilona Galántai, Csongor Kiss

Research output: Contribution to journalArticle

21 Citations (Scopus)


To prevent acute renal failure in children at risk for developing tumor lysis syndrome due to acute lymphoblastic leukemia or non-Hodgkin's lymphoma treated according to international BFM protocols, we investigated recombinant urate oxidase (rasburicase) in the first Central European open-labeled, prospective, multicenter phase IV trial. Rasburicase was administered intravenously, at 0.2 mg/kg for 5 consecutive days to 36 patients. Blood levels of uric acid, creatinine, phosphorus, calcium, lactate dehydrogenase and complete blood count were measured daily during rasburicase treatment and on days 6, 7 and 12. Initial uric acid level decreased significantly by 4 hours (from 343 μmol/L to 58 μmol/L, p<0.001), except for one steroid-resistant patient who required hemodialysis on day 14 after having introduced combined cytostatic treatment. Comparing the data of a subgroup of 12 patients receiving rasburicase with that of a historic cohort of 14 patients treated with allopurinol indicated the superiority of rasburicase over allopurinol in prophylaxis and treatment of hyperuricemia in children with leukemia and lymphoma.

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalPathology and Oncology Research
Issue number1
Publication statusPublished - Mar 31 2007


  • Leukemia
  • Lymphoma
  • Rasburicase
  • Tumor lysis syndrome
  • Uric acid

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

  • Cite this